Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated Hepatitis

Summary

The trial is designed as a prospective, single center, open label, randomized controlled pilot study evaluating the effect of A1AT (Alpha 1 Antitrypsin) on inflammation in patients with severe AAH (alcohol-associated hepatitis). The objective is to evaluate the safety and the effect of intravenous A1AT on the systemic inflammation in patients with severe AAH. The objectives also include the assessment of A1AT on clinical outcomes including the incidence of adverse events (AEs) and serious adverse events (SAEs) and the cytokine.

Timeline

Start

2025-04

Primary completion

2025-07

Completion

2026-12

Drugs

Indications